Immune-related adverse events up with checkpoint inhibitors

January 4, 2018

(HealthDay)—Although patients with pre-existing autoimmune disease who receive checkpoint inhibitors (CPIs) are at risk for exacerbation of their disease, immune-related adverse events (irAEs), or both, events can often be managed without discontinuing CPIs, according to a review published online Jan. 2 in the Annals of Internal Medicine.

Noha Abdel-Wahab, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a systematic review to summarize the evidence on associated with CPIs in patients with cancer and pre-existing autoimmune disease. Data were included from 123 patients identified in 49 publications.

The researchers found that 75 percent of the patients had exacerbations of pre-existing autoimmune disease, irAEs, or both. Patients with active and inactive disease did not differ in terms of adverse events. Fewer adverse events seemed to occur among patients receiving at initiation of CPI therapy than in those not receiving treatment. Most of the flares and irAEs were managed with corticosteroids; other immunosuppressive therapies were required by 16 percent. In more than half of the patients, adverse events improved without discontinuation of CPI therapy. Three died because of adverse events.

"Prospective longitudinal studies are needed to establish incidence of adverse events and evaluate risk-benefit ratios and patient preferences in this population," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: Checkpoint inhibitors no less safe with radiation

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Checkpoint inhibitors no less safe with radiation

September 29, 2017
(HealthDay)—Immune-related adverse events (IRAEs), including pneumonitis, are not more common in patients with metastatic lung cancer who receive both immune checkpoint inhibitors (CPIs) and thoracic radiotherapy (TRT), ...

LAMA plus LABA tied to fewer exacerbations in stable COPD

October 4, 2017
(HealthDay)—Treatment with long-acting muscarinic antagonists (LAMA) plus long-acting β-agonists (LABA) is associated with fewer exacerbation events in patients with chronic obstructive pulmonary disease (COPD), according ...

Continuing statin after adverse Rx tied to lower cardiac risk

July 25, 2017
(HealthDay)—For patients with an adverse reaction to a statin, continued statin prescriptions are associated with lower incidence of cardiovascular events and death, according to a study published online July 25 in the ...

Melanoma therapy tied to cutaneous adverse events

March 16, 2016
(HealthDay)—Anti-programmed cell death (PD)-1 therapy for metastatic melanoma is associated with the development of immune-related cutaneous events, according to research published in the March issue of the Journal of the ...

Immune checkpoint inhibitor endocrine dysfunction explored

September 29, 2017
(HealthDay)—Patients receiving immune checkpoint inhibitor (ICI) regimens may experience endocrine dysfunction, with increased risk of thyroid dysfunction and hypophysitis for patients on combination therapy, according ...

Preemies have lasting risk for anesthesia adverse events

February 26, 2016
(HealthDay)—Preterm children have an increased risk of developing sedation/anesthesia adverse events, which continues up to age 23 years, according to a study published online Feb. 25 in Pediatrics.

Recommended for you

Enzyme that triggers autoimmune responses from T-cells in patients with MS found

October 11, 2018
A team of researchers from Switzerland, the U.S. and Spain has isolated an enzyme that triggers an autoimmune response from T-cells in patients with MS. In their paper published in the journal Science Translational Medicine, ...

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

Eczema drug restores hair growth in patient with longstanding alopecia

October 10, 2018
Massachusetts General Hospital (MGH) physicians are reporting an unexpected side-effect from treatment with dupilumab, which is FDA approved for the treatment of moderate to severe eczema, also called atopic dermatitis. In ...

Clues to lupus's autoimmune origins in precursor cells

October 10, 2018
In the autoimmune disease systemic lupus erythematosus or SLE, the immune system produces antibodies against parts of the body itself. How cells that produce those antibodies escape the normal "checks and balances" has been ...

Scientists discover a new way to eliminate allergen-induced asthma attacks

October 9, 2018
Around the globe, an estimated 235 million people suffer from asthma. Most people are able to manage their symptoms and live healthy, active lives. However, for some, current treatments are not effective. Managing symptoms ...

'Double agent' in the immune system may make us vulnerable to bacterial infections

October 4, 2018
Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.